Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.

BACKGROUND The purpose of this study was to evaluate the significance of the combination of the carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels as a prognostic indicator and for monitoring for recurrence and metastasis after potentially curative surgery for patients with stage II colorectal cancer. PATIENTS AND METHODS A total of 238 patients with stage II colorectal cancer who underwent potentially curative surgery were enrolled in the study. A high CEA level was defined as a level exceeding 5 ng/ml and a high CA19-9 level was defined as a level exceeding 37 U/ml. RESULTS Out of these 238 patients, 92 (38.7%) patients had high CEA levels, 23 (9.7%) patients had high CA19-9 levels and 15 (6.3%) patients had both high CEA and CA19-9 levels. The disease-free and overall survival rates were significantly worse in patients with both a high CEA level and high CA19-9 level. Tumor marker(s) elevated before the operation tended to be elevated again at the time of relapse. CONCLUSION The combination of preoperative CEA and CA19-9 levels was useful for predicting the prognosis and for monitoring recurrence and metastasis after potentially curative surgery in patents with stage II colorectal cancer.

[1]  A. Arezzo,et al.  Surveillance after colorectal cancer surgery. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  K. Mizokami,et al.  First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs. , 2010, Clinical colorectal cancer.

[3]  V. Zurawski,et al.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. , 1983, Clinical chemistry.

[4]  M. Brouwers,et al.  Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Shung-Haur Yang,et al.  Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? , 2005, The Journal of surgical research.

[6]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Shung-Haur Yang,et al.  Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis , 2012, International Journal of Colorectal Disease.

[8]  M. W. Riley,et al.  Serum sialic acid and carcinoembryonic levels in the detection and monitoring of colorectal cancer , 1990, Diseases of the colon and rectum.

[9]  S. Yoshida,et al.  An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer , 2007, British Journal of Cancer.

[10]  Hiroki Takahashi,et al.  Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year , 2011, Surgery Today.

[11]  E. Campo,et al.  Prognostic value of CA 19.9 levels in colorectal cancer. , 1992, Annals of surgery.

[12]  H. Pahl,et al.  Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. , 1997, Anticancer research.

[13]  Abraham Fuks,et al.  Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule , 1989, Cell.

[14]  G. Choi,et al.  Serum Carcinoembryonic Antigen Monitoring After Curative Resection for Colorectal Cancer: Clinical Significance of the Preoperative Level , 2009, Annals of Surgical Oncology.

[15]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[16]  D. Radice,et al.  The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. , 2012, American journal of clinical pathology.

[17]  Z. Arikanoglu,et al.  Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. , 2011, Hepato-gastroenterology.

[18]  S. Yoshida,et al.  Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. , 2006, Japanese journal of clinical oncology.

[19]  Y. Ohashi,et al.  Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial , 2002, Langenbeck’s Archives of Surgery.

[20]  R. Mayer,et al.  The Use of Preoperative Plasma CEA Levels for the Stratification of Patients After Curative Resection of Colorectal Cancers , 1980, Annals of surgery.

[21]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  K. Miyazaki,et al.  Clinical Significance of CEA and CA19-9 in Postoperative Follow-up of Colorectal Cancer , 2010, Annals of Surgical Oncology.

[23]  R. Sorelle.  US Department of Health and Human Services gives states wider latitude in choosing services to be covered by Medicaid. , 2001, Circulation.

[24]  Toshiaki Watanabe,et al.  Recent approaches to identifying biomarkers for high-risk stage II colon cancer , 2012, Surgery Today.

[25]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[26]  S. Levitus,et al.  US Government Printing Office , 1998 .